Document |
Document Title |
JP2012503025A |
The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.
|
JP4860820B2 |
The present invention relates to methods for producing a heterologous polypeptide, comprising: (a) cultivating a mutant of a parent filamentous fungal cell under conditions conducive for the production of the heterologous polypeptide, wh...
|
JP4843614B2 |
The invention relates to nonadepsipeptides and processes for their preparation, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.
|
JP4824890B2 |
Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for th...
|
JP4810784B2 |
The present invention relates to reduced FK228 of the formula (I) wherein R<1> and R<2> are the same or different and each is a hydrogen atom or a thiol-protecting group, or a salt thereof, and a histone deacetylase inhibitor containing ...
|
JP4779971B2 |
A compound of formula I: or a pharmaceutically acceptable salt thereof, in combination with a topoisomerase II inhibitor, except amrubicin and a pharmaceutically acceptable salt thereof, for use in treatment of cancer.
|
JP2011523560A |
A pharmaceutical composition can be used for treating or preventing cancer; the composition comprising a pharmaceutically acceptable carrier and a peptide, a nucleic acid encoding said peptide, a vector comprising said nucleic acid, or a...
|
JP2011084585A |
To provide an alternative immunosuppressant having low cytotoxicity characteristics and controllable side effects.Depsipeptides and congeners thereof having structure (I) are disclosed, wherein m, n, p, q, X, R1, R2 and R3 are as defined...
|
JP2011006420A |
To provide an NS3 protease-inhibitive new compound.There are provided a new peptide analog which is a macrocyclic compound advantageous as an HCV (hepatitis C virus) NS3 protease inhibitor, a pharmaceutical composition containing such an...
|
JP4599567B2 |
There is provided a temperature responsive polymer compound which comprises a repeating unit represented by the following general formula (I): €ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ€ƒ-R 1 -Hmb-R 2 -€ƒ€ƒ€ƒ€ƒ€ƒ(I) where, Hmb...
|
JP4588634B2 |
A gene transfer efficiency enhancer of the present invention which contains a histone deacetylase inhibitor (especially compound (A)) as an active ingredient is capable of enhancing gene transfer efficiency in a gene transfer mediated by...
|
JP2010265271A |
To provide a targeted cytotoxic compound and a method related to its therapeutic use for the treatment of neoplasia and other conditions. This targeted cytotoxic compound is provided by including a cytotoxic part bonded with a targeted p...
|
JP2010222361A |
To provide a medical or a veterinary preparation for defence from endoparasites.The medical or veterinary pharmaceutical preparation for the control of endoparasites comprises didepsipeptides, salts, optical isomers or racemic forms of t...
|
JP4557232B2 |
The invention relates to nonadepsipeptides and process for their preparation, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.
|
JP4493327B2 |
|
JP4399160B2 |
The present invention provides methods inhibiting formation of neurofibrillary tangles; and methods for treating disorders relating to apolipoprotein E (apoE) in a subject. The methods generally involve reducing the level of a carboxyl-t...
|
JP4386209B2 |
Peptide mimicks of MUC1 or other cancer peptides which can be included in cancer vaccines and used in therapeutic methods for the treatment of cancer patients.
|
JPWO2007145306A1 |
A phospholipid derivative (1) containing a residue of an alcohol compound and a residue of phospholipids and containing a peptide between the residue of the alcohol compound and the residue of phospholipid, and the above without the inte...
|
JP4359238B2 |
Identifying a compound (I) that binds specifically to the G protein-coupled receptor mas-like-1 (R) by (i) treating at least one cell that expresses R on its surface (or a preparation of the cells that contains R) with at least one test ...
|
JP4326178B2 |
B-Group streptogramin compounds of formula (I):are useful as antimicrobial agents, optionally combined with at least one A-group streptogramin compound.
|
JP2009521917A |
The invention relates to phenylalanine, cysteine, derivatives of said amino acids, peptides comprising them, and to their use in diseases disorders or conditions whose pathology is caused by or associated with CXCR4 activity and/or cell ...
|
JP4277015B2 |
PCT No. PCT/FR95/01025 Sec. 371 Date Jan. 31, 1997 Sec. 102(e) Date Jan. 31, 1997 PCT Filed Jul. 31, 1995 PCT Pub. No. WO96/04299 PCT Pub. Date Feb. 15, 1996Streptogramine derivatives of general formula (I) below, wherein the radical R1 ...
|
JP4254972B2 |
Peptides having the formula: T-Gly-Val-D-Ile-Thr-Arg-Ile-U, V-Gly-D-Val-Ile-D-Thr-D-Arg-D-Ile-W, X-D-Arg-D-Ile-D-Arg-D-Thr-Ile-D-Val-Y, and Z-Gly-Val-Ile-Thr-Arg-Ile-U wherein T is absent or is selected from N-protecting group and a poly...
|
JP4227520B2 |
The present invention relates to compounds which bind selectively to the adhesion molecule human P-selectin, and particularly to such compounds comprising a peptide with an amino acid sequence XAxA3A1A2A1Y, or a functional equivalent of ...
|
JP4223810B2 |
The present invention provides a rapid and inexpensive method for extractively isolating acidic lipopeptide antibiotics, such as those having a cyclic peptide or cyclic depsipeptide core, in high yield and purity. In particular, there is...
|
JP4176077B2 |
The present invention is comprised of culturing microorganism having ability to produce FKI-1033 substance represented by the formula: in a medium, accumulating FKI-1033 substance in the cultured medium, and isolating FKI-1033 substance ...
|
JP4163746B2 |
PCT No. PCT/EP95/04255 Sec. 371 Date May 2, 1997 Sec. 102(e) Date May 2, 1997 PCT Filed Oct. 30, 1995 PCT Pub. No. WO96/15121 PCT Pub. Date May 23, 1996The present invention relates to the use of dioxomorpholines of the formula (I) (I) i...
|
JP4160149B2 |
|
JP4156235B2 |
An objective of the present invention is to provide a transformant altered so as to produce a secondary metabolite in which a benzene ring of the secondary product is modified at the para-position with a functional group containing a nit...
|
JP2008517006A |
Nonadepsipeptides and methods for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases are described.
|
JP2008517004A |
The invention relates to nonadepsipeptides and methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.
|
JP2008092952A |
To provide an effective method for preparation of substituted aryl lactic acid containing cyclodepsipeptides.The invention relates to the new method for the preparation of substituted aryl lactic acid containing cyclodepsipeptides with 2...
|
JP4054576B2 |
By culturing Lysobacter sp. BMK333-48F3 (deposit number of FERM BP-7477), an antibiotic, tripropeptin Z, tripropeptin A, tripropeptin B, tripropeptin C or tripropeptin D represented by the general formula (I): wherein R is 7-methyl-octyl...
|
JP4054063B2 |
PCT No. PCT/EP96/05190 Sec. 371 Date Jun. 4, 1998 Sec. 102(e) Date Jun. 4, 1998 PCT Filed Nov. 25, 1996 PCT Pub. No. WO97/20945 PCT Pub. Date Jun. 12, 1997The present invention relates to a new process for the preparation of substituted ...
|
JP4033920B2 |
Endoparasitic activity of cyclic depsipeptides (I) comprising amino acid and hydroxycarboxylic acid units and having 6-30 ring atoms is increased by praziquantel (II) and epsiprantel (III). An endoparasitic agent contg. (I) together with...
|
JP2007314580A |
To enhance the endoparasiticidal activity of cyclic depsipeptides. The present invention relates to the use of praziquantel and epsiprantel for enhancing the endoparasiticidal activity of cyclic depsipeptides in endoparasiticidal composi...
|
JP3987909B2 |
The present invention relates to a novel compound which is useful as an agent for prevention and treatment of diseases associated with HDAC, in particular, tumor or cell proliferative diseases. The depsipeptide compound or its pharmaceut...
|
JP3990284B2 |
Strains belonging to the genus Pseudomonas; and antiviral agents containing as the active ingredient at least one member selected from among peptides, derivatives and salts thereof and the novel strains.
|
JP3947229B2 |
Depsipeptides represented by the formula (1): (wherein: R1 is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15 carbon atoms; R2 is -A-B, -A-B-W, -A-B-W-D or -A-B-W-D-E, R3 is a ...
|
JP2007125021A |
To provide an assay for identifying a β-selectase inhibitor and a method for screening.The assay for identifying the β-selectase inhibitor comprises a step of immobilizing a β-selectase protein on a solid support, a step of bringing t...
|
JP3910634B2 |
A method for transforming strain PF1022, which produces a cyclic depsipeptide (substance PF1022) and belongs to the order Agonomycetales of the class Hyphomycetes have established by using a plasmid constructed with a promoter, a termina...
|
JP3893030B2 |
To provide a new lipopolysaccharide absorbent (a bacterial endotoxin absorbent) and a screening method for the same capable of easily synthesizing, easily controlling various similar structures, and using in absorbing various lipopolysac...
|
JP2007056046A |
To provide a polydepsipeptide equipped with both temperature-responding property and biodegradable property suitable as a medical material, and a method for producing the same.This polydepsipeptide is expressed by general formula (I) [wh...
|
JP2007031434A |
To provide a streptogramin derivative which is a new pseudopeptide, namely a new antibiotic derivative.The streptogramin derivative is represented by general formula of the figure (wherein R1 is ethyl and R2 and X are each H and Y is H o...
|
JP2006527772A |
The present invention provides methods of treating metabolic disorders, including, for example, obesity, diabetes mellitus, cachexia, sarcopenia, and cardiovascular disorders, methods of inducing weight loss and increasing muscle mass in...
|
JP2006523214A |
The present invention is directed to a compound of Formula I wherein R1, R2, R3, R4, R5, R6, W, X, Y, and Z are defined herein. The compounds of the present invention are useful as anticancer agents. Specifically, the compounds are usefu...
|
JP3830964B2 |
The present invention is directed to a novel depsipeptide has been isolated from a new marine strain L-13-ACM2-092 belonging to the family Micromonosporaceae. Its production by aerobic fermentation under controlled conditions of the stra...
|
JP3798825B2 |
PURPOSE: To combat endoparasites in human, domestic animals and pet animals by using an open-chain tetradepsipeptide. CONSTITUTION: This compound is an open-chain tetradepsipeptide represented by formula I (A is H, an alkyl, aralkyl or a...
|
JP3798824B2 |
PURPOSE: To combat endoparasites in human, domestic animals and pet animals by using an open-chain hexadepsipeptide. CONSTITUTION: This compound is represented by formula I (A is H, an alkyl, aralkyl, an aryl, acyl or the like; R1, R3 an...
|
JP2006180840A |
To obtain a polypeptide that has hardly adverse effect, is produced without requiring such a high technique and a plenty of people, promotes plasmin activity, t-PA activity and urokinase activity and a use thereof.The polypeptide promote...
|